Fagundes M A, Hug E B, Liebsch N J, Daly W, Efird J, Munzenrider J E
Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, USA.
Int J Radiat Oncol Biol Phys. 1995 Oct 15;33(3):579-84. doi: 10.1016/0360-3016(95)02014-3.
To determine the patterns of failure and outcome following relapse of chordomas of the base of skull and cervical spine.
Between November 1975 and October 1993, 204 patients were treated for chordoma of the base of skull or cervical spine, of which 63 have developed relapse. These 63 patients constitute the main focus of this study. Forty-five patients presented with base of skull and 18 with cervical spine tumors. All patients received combined proton and photon beam radiation. The median prescribed dose was 70.1 cobalt-Gray equivalent (CGE) (range 66.6-77.4). There were 25 males and 38 females, with a median age of 41 years (range 7-66). Median follow-up was 54 months (range 8-158).
Sixty-three of the 204 patients treated (31%) had treatment failure. Among the 63 patients who relapsed, 60 (95%) experienced local recurrence, and in 49 patients (78%), this was the only site of failure. Two of 63 patients (3%) developed regional lymph node relapse and 3 of 63 (5%) developed surgical pathway recurrence (1 left neck, 1 palate and 1 nasal cavity). Thirteen of 204 patients relapsed in distant sites, accounting for 20% (13 of 63) of all patients with recurrence in this series. The most common metastatic sites were lungs and bones presenting in 7 of 13 and 6 of 13 patients, respectively. Only 2 of 13 patients failed with isolated distant metastasis. The actuarial 3- and 5-year survival rates after local relapse (60 patients) were 44 and 5%, respectively. Following distant failure (13 patients), the 3- and 5-year survival rates were 25 and 12%, respectively. After any relapse (63 patients) the corresponding survival rates were 43 and 7%. Following local relapse, 49 of 60 patients underwent salvage therapy consisting of subtotal resection in most patients (46 of 49). The remaining 11 of 60 patients received supportive care only. Salvage therapy resulted in stable or improved status without subsequent disease progression in 26 of 49 (53%), and progressive disease in 16 of 49 patients (33%). The actuarial 2- and 5-year overall survival rates following relapse for the 49 patients who underwent salvage treatment were 63 and 6%, which favorably compared to the 2-year survival rate of 21% for those who received supportive care only (p = 0.001).
Local relapse is the predominant type of treatment failure for chordomas of the base of skull and cervical spine. Salvage treatment may relieve symptoms; however, most patients will ultimately succumb to their disease. Poor long-term survival rates following relapse emphasize the importance of a combined treatment approach with experienced surgeons and radiation oncologists at the time of primary treatment. For most patients, only permanent local tumor control will offer a chance of cure.
确定颅底和颈椎脊索瘤复发后的失败模式及预后。
1975年11月至1993年10月期间,204例患者接受了颅底或颈椎脊索瘤治疗,其中63例出现复发。这63例患者构成了本研究的主要对象。45例患者为颅底肿瘤,18例为颈椎肿瘤。所有患者均接受质子和光子束联合放疗。规定剂量的中位数为70.1钴 - 格雷当量(CGE)(范围66.6 - 77.4)。男性25例,女性38例,年龄中位数为41岁(范围7 - 66岁)。中位随访时间为54个月(范围8 - 158个月)。
204例接受治疗的患者中有63例(31%)治疗失败。在63例复发患者中,60例(95%)出现局部复发,49例(78%)患者仅该部位出现失败。63例患者中有2例(3%)出现区域淋巴结复发,3例(5%)出现手术路径复发(1例左侧颈部、1例腭部和1例鼻腔)。204例患者中有13例出现远处复发,占本系列所有复发患者的20%(63例中的13例)。最常见的转移部位是肺和骨,分别有13例中的7例和13例中的6例患者出现。13例患者中仅有2例因孤立性远处转移而失败。局部复发(60例患者)后的3年和5年精算生存率分别为44%和5%。远处失败(13例患者)后,3年和5年生存率分别为25%和12%。任何复发(63例患者)后的相应生存率为43%和7%。局部复发后,60例患者中有49例接受了挽救治疗,大多数患者(49例中的46例)接受了次全切除。其余60例患者中的11例仅接受了支持性治疗。挽救治疗使49例中的26例(53%)患者病情稳定或改善且无后续疾病进展,49例中的16例(33%)患者病情进展。接受挽救治疗的49例患者复发后的2年和5年总精算生存率分别为63%和6%,与仅接受支持性治疗患者的2年生存率21%相比有显著优势(p = 0.001)。
局部复发是颅底和颈椎脊索瘤治疗失败的主要类型。挽救治疗可能缓解症状;然而,大多数患者最终仍会死于疾病。复发后较差的长期生存率强调了在初次治疗时由经验丰富的外科医生和放射肿瘤学家采用联合治疗方法的重要性。对于大多数患者,只有实现永久性局部肿瘤控制才有治愈的机会。